
Breast cancer experts discuss adverse effect management when using breast cancer therapies targeting the PI3K, AKT, and mTOR pathways.

Your AI-Trained Oncology Knowledge Connection!


Neil Iyengar, MD, is an associate professor in the Department of Hematology and Medical Oncology and co-director of Breast Medical Oncology in the Department of Hematology and Medical Oncology at Emory University School of Medicine; as well as director of Survivorship Services at the Winship Cancer Institute of Emory University.

Breast cancer experts discuss adverse effect management when using breast cancer therapies targeting the PI3K, AKT, and mTOR pathways.